ModifiedUnitedHealthcarePolicy N/A

Lower Extremity Endovascular Procedures (for New Mexico Only)

Policy governs medical necessity coverage for endovascular revascularization procedures (e.g., angioplasty, stenting, atherectomy, and DETOUR endovenous femoropopliteal bypass) for treatment of lower extremity peripheral artery disease including claudication and chronic limb-threatening ischemia (CLTI); includes documentation requirements and references to clinical evidence and guidelines.

Policy Summary

PayerUnitedHealthcare

PolicyLower Extremity Endovascular Procedures (for New Mexico Only)

Policy CodePolicy N/A

Change TypeRevised coverage criteria; added retreatment criteria; documentation updates

Effective DateFebruary 1, 2026

Next Review DateN/A

Key ActionEnsure the patient medical record documents history, exam, and diagnostic imaging (showing ≥50% stenosis or alternate imaging) to support medical necessity before requesting coverage.

POLICY UPDATE CHANGES

Revised medically necessary coverage criteria for endovascular revascularization procedures for non-limb-threatening lower extremity ischemia in individuals with Claudication.

Added language that retreatment for in-stent restenosis is proven and medically necessary when specific criteria are met (recurrent symptoms, impaired ADLs/ability to work, and imaging showing >=50% stenosis).

Added documentation requirements indicating medical records must fully support medical necessity and may be requested for review.

Archived previous policy version CS166NM.B.

Updated Clinical Evidence and References sections to reflect current information.

2Major clinical populations addressed (Claudication; CLTI)

50%

Coverage Summary

This policy addresses medical necessity coverage for endovascular revascularization procedures for lower extremity peripheral artery disease (PAD), including angioplasty, stenting, atherectomy, and the DETOUR endovenous femoropopliteal bypass. The policy applies to treatment of symptomatic PAD presenting as Claudication and Chronic Limb-Threatening Ischemia (CLTI) and includes documentation and evidence requirements to support coverage decisions. Status: MODIFIED. Last review: 2026-02-01; Effective date: February 1, 2026.

Key thresholds and quick facts

Stenosis threshold for coverage (50%)Imaging must show an anatomic location and a moderate-severe stenosis (50% or greater) for target vessels before coverage; if duplex does not show ≥50%, another imaging modality (CTA, MRA, or digital subtraction angiography) is required

Major clinical populations addressedClaudication (non-limb-threatening lower extremity ischemia) and Chronic Limb-Threatening Ischemia (CLTI) when revascularization is indicated

Noted FDA-approved device/system (informational)DETOUR System (TORUS stent graft and ENDOCROSS Device) — FDA PMA P220021; approved for percutaneous revascularization in symptomatic femoropopliteal lesions meeting specified length/CTO criteria

IWGDF pressure thresholds (informational)Consider urgent vascular imaging and revascularization for ankle pressure < 50 mm Hg or ABI < 0.4; consider urgent assessment if toe pressure < 30 mm Hg or TcPO2 < 25 mm Hg

Medically Necessary and Retreatment Criteria

Medically Necessary Coverage Criteria for Endovascular Revascularization (non-limb-threatening Claudication and CLTI)

Covered when ALL of the following are met:

Medically necessary criteria

Diagnosis of Claudication due to atherosclerotic disease of the aortoiliac and/or femoropopliteal arteries OR chronic limb-threatening ischemia (CLTI) when revascularization is indicated
Imaging stenosis threshold: Imaging results of the target vessel (e.g., duplex ultrasound, CTA, MRA, or digital subtraction angiography) show anatomic location and a moderate-severe stenosis (50% or greater)50% or greater
Reflects guideline recommendations cited (ACC/AHA, SVS)
Conservative therapy for claudication:

Procedures with Insufficient Evidence or Investigational Status

Procedures/Techniques with Insufficient Evidence or Investigational Status

Not established as proven/medically necessary when evidence insufficient or investigational:

Investigational/Insufficient Evidence Procedures

Iliac artery atherectomy — insufficient quality evidence to support safety and efficacy; uncommon due to risk of life-threatening perforation
DETOUR endovenous femoropopliteal bypass — studies ongoing; evidence described as very-low- to low-quality and single-arm; larger randomized comparisons and long-term data needed
FDA informational status noted elsewhere; evidence currently insufficient for proven/medically necessary

Certain techniques are designated investigational or have insufficient evidence because available studies are low-quality, nonrandomized, or single-arm and do not provide comparative long-term outcomes. For iliac artery atherectomy, most evidence is retrospective or single-arm, limiting generalizability, and the technique is uncommon due to reports of life‑threatening perforation. For the DETOUR endovenous femoropopliteal bypass, existing data are from single-arm studies (DETOUR I and DETOUR2) that demonstrate technical success and promising short-term patency but lack randomized comparisons and long-term follow-up; larger randomized trials and longer-term outcome data are needed to establish safety and effectiveness.

Referenced Imaging and Devices

Referenced imaging modalities (diagnostic evidence requirement)mixed

	Duplex ultrasound
	Computed tomography angiography (CTA)
	Magnetic resonance angiography (MRA)
	Digital subtraction angiography (invasive angiography)

Devices/Systems discussed (informational, FDA status noted)mixed

DETOUR System (TORUS stent graft and ENDOCROSS Device)

FDA PMA P220021; approved for percutaneous revascularization in symptomatic femoropopliteal lesions 200-460 mm with CTO 100-425 mm or diffuse stenosis >70% (informational only)

This brief did not provide an exhaustive list of CPT, HCPCS, or ICD codes as binding billing guidance. The policy includes a code table that lists procedure and diagnosis codes for reference only; listing a code does not imply coverage or reimbursement. Coders and billing staff should follow specific payer coding guidance and applicable contractual or state requirements when submitting claims.

Prior Authorization, Documentation, and Denial Risks

Documentation Required

Medical record documentation required

The patient's medical record must fully document the history, physical exam, and relevant diagnostic test/procedure results to support medical necessity; records must be legible, maintained, and available upon request.

Prior Authorization

Evidence required for imaging demonstration

If duplex ultrasound does not show a stenosis of 50% or greater, coverage requires another imaging modality to demonstrate the extent of stenosis; acceptable modalities include CTA, MRA, or digital subtraction (invasive) angiography.

Computed tomography angiography (CTA)
Magnetic resonance angiography (MRA)
Digital subtraction angiography (invasive angiography)

Clinical Background and Evidence Summary

Peripheral artery disease (PAD) is narrowing of lower extremity arteries from atherosclerosis that reduces limb blood flow and can cause claudication and, if untreated, progress to chronic limb-threatening ischemia (CLTI). Treatment options include lifestyle modification and medical therapy, supervised exercise programs, endovascular interventions (balloon angioplasty, stents, endovenous stent grafts, atherectomy), and open surgical bypass. Choice of revascularization technique is individualized and depends on lesion characteristics such as anatomic location, lesion length, and degree of calcification, as well as patient risk and goals of care.

Study/Source	Key findings
BEST-CLI (Farber et al., 2022)	Cohort 1 (suitable GSV): surgical bypass had significantly lower rate of major adverse limb event or death than endovascular; Cohort 2 (no suitable GSV): outcomes were similar. Median follow-up 2.7 and 1.6 years respectively.
Pegler et al. (2025) meta-analysis	Systematic review/meta-analysis of RCTs (n=3840): no significant difference in major amputation or mortality between bypass and endovascular; bypass had lower reintervention rate.
Cochrane (Fakhry et al., 2018)	Review of trials (n=1,087): endovascular revascularization and supervised exercise are comparable for improving walking distance and quality of life in intermittent claudication; combination therapy may provide greater improvements.
DETOUR2 trial (Lyden et al., 2024)	Single-arm prospective study (n≈200 treated): 1‑year primary patency 72.1%; 30‑day freedom from major adverse events 93.0%; 12‑month DVT incidence 4.1%; marked improvements in ABI, Rutherford class, QoL; limited by single-arm design and lack of randomized comparison.
Iliac artery atherectomy evidence summary	Insufficient quality evidence (mostly retrospective, single‑arm, nonrandomized); limited generalizability and risk of life‑threatening perforation; atherectomy of the iliac artery is uncommon due to perforation risk.

Claudication: leg fatigue, cramping, aching, pain, or other vascular-origin discomfort in the lower extremity muscles that is consistently induced by walking and relieved by rest (usually within about 10 minutes).

Chronic Limb-Threatening Ischemia (CLTI): advanced PAD characterized by chronic (≥2 weeks) ischemic rest pain, nonhealing ulcers/wounds, or gangrene attributable to arterial occlusive disease, and associated with high risk of limb loss and cardiovascular events.

Policy Revision History

02/01/2026revisedLatest

Revised medically necessary coverage criteria for endovascular revascularization for non-limb-threatening lower extremity ischemia (claudication); imaging criterion replaced to require that imaging of the target vessel show anatomic location and a moderate-severe stenosis (50% or greater).

02/01/2026addedLatest

Added coverage language that retreatment for in-stent restenosis is proven and medically necessary when all criteria are met (recurrent symptoms, impaired ADLs/ability to work, and imaging of previously treated vessel showing a moderate-severe stenosis ≥50%); specifies if duplex does not show ≥50% stenosis another imaging modality is required.